FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 2, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Sticker Shock: Ophthalmic Bevacizumab Biosimilar Could Drive Up Costs
(MedPage Today) -- SEATTLE -- Availability of a bevacizumab (Avastin) biosimilar for ophthalmic use could have the unintended consequence of driving up the cost of treating retinal disease with angiogenesis inhibitors, according to an economic... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 1, 2023 Category: American Health Source Type: news

What Are Treatments for Recurrent Respiratory Papillomatosis?
Discussion Human papilloma virus (HPV) is a member of the Papillomaviridae virus family with over a 150 different subtypes. HPV can cause cervical, genital and respiratory tract papillomas. HPV is often benign but can cause anogenital, cervical and head and neck cancers. Recurrent respiratory papillomatosis (RRP) is uncommon but can cause significant morbidity while awaiting the body’s immune system to respond. There is a juvenile and adult form, and the incidence varies between 2-4/100,000 in the pediatric population. The juvenile form frequently occurs between 3.6-6 years of age and in general the younger the patie...
Source: PediatricEducation.org - July 31, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news

Can AI Help Determine If Liver Cancer Will Respond to Standard Treatment?
(MedPage Today) -- VIENNA -- Researchers trained an artificial intelligence (AI) model to determine if a patient with hepatocellular carcinoma (HCC) will respond to standard treatment with atezolizumab (Tecentriq) plus bevacizumab (Avastin)... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 26, 2023 Category: Gastroenterology Source Type: news

Trial Suggests Optimal Approach to Unresectable CRC Liver Mets
(MedPage Today) -- For patients with initially unresectable colorectal cancer liver metastases, FOLFOXIRI plus bevacizumab (Avastin) was the "preferred" systemic induction regimen for those with a right-sided or RAS- or BRAF V600E-mutated primary... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 21, 2023 Category: Gastroenterology Source Type: news

ASCO: Adding Pembrolizumab to Chemo Improves Survival in Cervical Cancer
THURSDAY, June 1, 2023 -- For women with persistent, recurrent, or metastatic cervical cancer, adding pembrolizumab to chemotherapy, with or without bevacizumab, is associated with improved overall and progression-free survival, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 1, 2023 Category: Pharmaceuticals Source Type: news

Roche to present new data in blood cancers and solid tumours from its broad portfolio at ASCO 2023
Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, held 2 – 6 June. Highlights include new data spanning treatments for lymphoma and hepatocellular carcinoma (HCC):Developing new treatment options for people with blood cancersExtended follow-up data for Columvi ® (glofitamab) of almost two years (20 months) from the pivotal phase II NP30179 study, further investigating the potential of fixed-duration Columvi to provide durable responses in people...
Source: Roche Investor Update - May 26, 2023 Category: Pharmaceuticals Source Type: news

FTD-TPI Plus Bevacizumab Increases Survival in Refractory Advanced CRC
THURSDAY, May 4, 2023 -- Treatment with trifluridine-tipiracil (FTD-TPI) plus bevacizumab yields longer overall survival than FTD-TPI alone among patients with refractory metastatic colorectal cancer, according to a study published in the May 4... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of  Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news

Combo Therapy May Prevent Cancer's Return After Liver Surgery
MONDAY, April 24, 2023 -- A two-drug combination therapy can enhance survival odds for people with early-stage liver cancer through targeted attacks on tumor cells, a new clinical trial shows. The combo -- atezolizumab (Tecentriq) and bevacizumab... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 24, 2023 Category: General Medicine Source Type: news

Health Highlights: April 24, 2023 ​
Combo therapy may prevent cancer ' s return after liver surgery. Atezolizumab and bevacizumab are already used together to treat advanced liver cancer, now a new study finds it does the same for early-stage disease. Read more This is your brain on... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 24, 2023 Category: General Medicine Source Type: news

AACR: Adjuvant Atezolizumab + Bevacizumab Beneficial in Liver Cancer
TUESDAY, April 18, 2023 -- For patients with high-risk hepatocellular carcinoma (HCC), adjuvant therapy of atezolizumab with bevacizumab (atezo + bev) prolongs recurrence-free survival, according to a study presented at the annual meeting of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2023 Category: Pharmaceuticals Source Type: news